Biomoda (OTCBB: BMOD) has entered into a Memorandum of Understanding with the University of Texas Health Science Center at San Antonio to collaborate on research to optimize the CyPath® diagnostic assay for lung cancer.
According to John Cousins, President of Biomoda, “Our research will progress more quickly and our science will be strengthened by this initiative. Biomoda is focused on optimization of its assay to include automating sample reading through flow cytometry and refining the use of fluorescent microscopy to identify cancer cell types and pre-cancerous cells. The Health Science Center not only will greatly assist us with the science, but we believe the partnership has the potential to create jobs and economic growth for the region.”
